国内乙肝创新药物获突破性进展，港股创新药精选ETF(520690)最新份额超6亿份，创成立以来新高

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index decreased by 0.94% as of November 11, 2025, with mixed performance among constituent stocks [2] - China Resources Sanjiu announced a significant collaboration with Langyu Group and Bioproject to develop and commercialize the innovative drug for narcolepsy, indicating a strategic move into rare diseases [2] - The Hong Kong Innovative Drug Select ETF (520690) fell by 0.56%, with a latest price of 0.89 yuan and a turnover rate of 7.74%, amounting to 42.24 million yuan [2] Group 2 - The 76th American Association for the Study of Liver Diseases (AASLD) annual meeting reported breakthrough results for HepaGene's innovative drug HepaPeptide in treating chronic hepatitis B, showing potential for sterilizing cure [3] - The innovative drug sub-sector's revenue grew by 23.34% year-on-year in the first three quarters of 2025, leading all sub-sectors and reflecting strong growth resilience [3] - The latest share count for the Hong Kong Innovative Drug Select ETF reached 608 million, a record high since its inception, with a net inflow of 8.016 million yuan recently [3] Group 3 - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [4] - As of October 8, 2025, the top ten weighted stocks in the index accounted for 72.15% of the total index, including companies like BeiGene and China Biologic Products [4]